Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs VanEck Uranium & Nuclear ETF (NLR) Price & Performance

VanEck Uranium & Nuclear ETFTrade

Price performance (Past 24H)

Key statistics

GSK plc vs VanEck Uranium & Nuclear ETF — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while VanEck Uranium & Nuclear ETF trades at $103.5 (market cap $3.51B). The key difference: GSK plc is far larger — about 26.2× VanEck Uranium & Nuclear ETF's market cap, and GSK plc pays a 3.9% dividend while VanEck Uranium & Nuclear ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and VanEck Uranium & Nuclear ETF for 8 Days on average.

GSKNLR
Market Cap
$91.88B$3.51B
Volume
7,730,529414,516
Sector
HealthSector/Thematic
52-Week High
$61.18$164.37
52-Week Low
$43.24$102.38
Typical Hold Time
93 Days8 Days
Enterprise Value
$111.88B—
Dividend Yield
3.9%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.

GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.

VanEck Uranium & Nuclear ETF

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GSK
100% Buy0% Sell
Avg holding period · 93 Days
NLR
0% Buy100% Sell
Avg holding period · 8 Days

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK →

About VanEck Uranium & Nuclear ETF

VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.

Read more on NLR →